Parkinson's Foundation PD GENEration Genetic Registry
1 other identifier
observational
25,000
3 countries
56
Brief Summary
Development of a central repository for PD-related genomic data for future research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2020
Longer than P75 for all trials
56 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 20, 2020
CompletedFirst Submitted
Initial submission to the registry
July 29, 2021
CompletedFirst Posted
Study publicly available on registry
August 6, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
May 21, 2025
May 1, 2025
5.5 years
July 29, 2021
May 16, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Prevalence of Parkinson's related genetic mutations in an convenience cohort
Identify people with Parkinson's who have genetic mutations to advance basic science and clinical research.
6 months
Educating people with Parkinson's of their genetic mutation status through genetic testing and counseling
People who are informed of their genetic status may be empowered to learn more about their disease and participant in clinical research.
6 months
Interventions
Counseling provided to participant by site clinician/physician/genetic counselor.
Eligibility Criteria
Any person with probable diagnosis of Parkinson's disease according to the Movement Disorders Society criteria.
You may qualify if:
- Study Population 1: PWP (open for recruitment)
- Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
- Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
- Capacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.
- Able to perform study activities (including completion of either online, in-person or paper surveys).
- Study Population 2: People at risk of developing PD (not open for recruitment)
- \. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.
You may not qualify if:
- Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
- Individuals who have received a blood transfusion within the past 3 months.
- Individuals who have active hematologic malignancies such as lymphoma or leukemia.
- Individuals who have had a bone marrow transplant within the past 5 years.
- Under the age of 18
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Parkinson's Foundationlead
- Indiana Universitycollaborator
- Fulgent Geneticscollaborator
- The Parkinson Study Groupcollaborator
Study Sites (56)
University of Alabama Birmingham
Birmingham, Alabama, 35294, United States
MD First Research
Chandler, Arizona, 85286, United States
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
University of Arkansas
Fayetteville, Arkansas, 72701, United States
University of California San Diego (UCSD)
La Jolla, California, 92093, United States
University of California Los Angeles
Los Angeles, California, 90095, United States
University of California San Francisco (UCSF)
San Francisco, California, 94143, United States
University of Colorado Anschutz
Aurora, Colorado, 80045, United States
Hartford Healthcare
Hartford, Connecticut, 06066, United States
Aventura Neurology - Visionary Investigators Network
Aventura, Florida, 33180, United States
Parkinson's Disease & Movement Disorder Center of Boca Raton
Boca Raton, Florida, 33486, United States
University of Florida
Gainesville, Florida, 32611, United States
University of Miami
Miami, Florida, 33131, United States
Cleveland Clinic Weston
Weston, Florida, 33331, United States
Morehouse College
Atlanta, Georgia, 30314, United States
The Queen's Health System
Honolulu, Hawaii, 96813, United States
University of Illinois-Chicago
Chicago, Illinois, 60607, United States
Rush University
Chicago, Illinois, 60612, United States
University of Chicago
Chicago, Illinois, 60637, United States
Northwestern University
Evanston, Illinois, 60208, United States
Indiana University
Indianapolis, Indiana, 46202, United States
University of Iowa
Iowa City, Iowa, 52242, United States
University of Kansas
Lawrence, Kansas, 66045, United States
University of Kentucky
Lexington, Kentucky, 40506, United States
Louisiana State University
Shreveport, Louisiana, 71103, United States
Johns Hopkins
Baltimore, Maryland, 21218, United States
University of Maryland
College Park, Maryland, 20742, United States
Massachusetts General Hospital (MGH)
Boston, Massachusetts, 02114, United States
BMC Community Hospital
Boston, Massachusetts, 02136, United States
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, 02215, United States
Struthers Parkinson's Center - HealthPartners Park Nicollet
Golden Valley, Minnesota, 55427, United States
Rutgers University
New Brunswick, New Jersey, 08854, United States
University of New Mexico
Albuquerque, New Mexico, 87106, United States
New York University
New York, New York, 10017, United States
Mount Sinai
New York, New York, 10029, United States
Columbia University
New York, New York, 10033, United States
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Atrium Health
Charlotte, North Carolina, 28207, United States
University of Cincinnati
Cincinnati, Ohio, 45221, United States
Case Western Reserve University
Cleveland, Ohio, 44106, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Ohio State University
Columbus, Ohio, 43210, United States
Oregon Health and Science University
Portland, Oregon, 97239, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19144, United States
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Vanderbilt University
Nashville, Tennessee, 37235, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
University of Texas at San Antonio
San Antonio, Texas, 78249, United States
Intermountain Health
Murray, Utah, 84107, United States
Virginia Commonwealth University
Richmond, Virginia, 23284, United States
Evergreen Health
Kirkland, Washington, 98034, United States
Inland Northwest Research
Spokane, Washington, 99202, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Toronto Western Hospital
Toronto, Ontario, Canada
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
Biospecimen
Isolated DNA from buccal swab or whole blood.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
James Beck, PhD
Parkinson's Foundation
- PRINCIPAL INVESTIGATOR
Roy N Alcalay, MS, MD
Tel Aviv Sourasky Medical Center, Columbia University Irving Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 30 Days
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 29, 2021
First Posted
August 6, 2021
Study Start
December 20, 2020
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
May 21, 2025
Record last verified: 2025-05